Cargando…

Real-Life Effectiveness of MP-AzeFlu (Dymista(®)) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale

BACKGROUND: Many allergic rhinitis (AR) patients have moderate/severe persistent disease. MP-AzeFlu (Dymista(®)) comprises intranasal azelastine hydrochloride and fluticasone propionate in a novel formulation delivered in a single device. OBJECTIVE: This prospective, noninterventional study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stjärne, Pär, Nguyen, Duc Tung, Kuhl, Hans Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826638/ https://www.ncbi.nlm.nih.gov/pubmed/36628265 http://dx.doi.org/10.2147/POR.S375403

Ejemplares similares

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy
por: Kaulsay, Ranbir, et al.
Publicado: (2018)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

MP‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children
por: Berger, W., et al.
Publicado: (2016)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu
por: Dollner, Ralph, et al.
Publicado: (2017)

Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
por: Roca-Ferrer, Jordi, et al.
Publicado: (2018)

Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R
por: Ekstedt, Sandra, et al.
Publicado: (2020)

A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis
por: Zhou, Bing, et al.
Publicado: (2023)

Effect of MP‐AzeFlu compared to monotherapy on COX‐2, PGE(2), and EP2 gene expression in upper airway mucosa
por: Vicens‐Artes, Sonia, et al.
Publicado: (2022)

Superior effect of MP‐AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP‐1 and TTP anti‐inflammatory gene expression in healthy and inflamed upper airway mucosa
por: Vicens‐Artés, Sònia, et al.
Publicado: (2022)

The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers
por: Qi, Wenyuan, et al.
Publicado: (2023)

Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells
por: Berger, William E, et al.
Publicado: (2020)

Real-life effectiveness of a new allergic rhinitis therapy (MP29-02*) in Sweden
por: Stjärne, Pär, et al.
Publicado: (2015)

A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US
por: Prenner, Bruce M
Publicado: (2016)

Persistent Allergic Rhinitis and the XPERT Study
por: Rogkakou, Anthi, et al.
Publicado: (2011)

Effects of corticosteroids on hyposmia in persistent allergic rhinitis
por: CATANA, IULIU V., et al.
Publicado: (2013)

Allergic Rhinitis Therapy Decisions During a Routine Consultation: A Multicenter, Cross-Sectional Survey
por: Gálffy, Gabriella, et al.
Publicado: (2021)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

Effects of Rhinophototherapy on Quality of Life in Persistant Allergic Rhinitis
por: Tatar, Emel Çadalli, et al.
Publicado: (2013)

373 Alteration of Smell in Patients with Persistent Allergic Rhinitis
por: De Barayazarra, Susana, et al.
Publicado: (2012)

Role of Predatory Mites in Persistent Nonoccupational Allergic Rhinitis
por: Poza Guedes, Paloma, et al.
Publicado: (2016)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

Dual systemic allergic rhinitis and local allergic rhinitis
por: Blanca, Miguel, et al.
Publicado: (2015)

Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine
por: Mullol, Joaquim, et al.
Publicado: (2005)

Sleep disorders in children with moderate to severe persistent allergic rhinitis()
por: Loekmanwidjaja, Jessica, et al.
Publicado: (2017)

Effect of Botulinum Neurotoxin A Injection into the Submucoperichondrium of the Nasal Septum in Reducing Idiopathic Non-Allergic Rhinitis and Persistent Allergic Rhinitis
por: Mozafarinia, Keramat, et al.
Publicado: (2015)

Genetic variation of the Toll-like receptors in a Swedish allergic rhinitis case population
por: Henmyr, V., et al.
Publicado: (2017)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

Allergic rhinitis
por: Small, Peter, et al.
Publicado: (2011)

Allergic rhinitis
por: Small, Peter, et al.
Publicado: (2018)

Validation and psychometric evaluation of the Swedish version of the Nasal Obstruction Symptom Evaluation scale
por: Sunnergren, Ola, et al.
Publicado: (2023)

Incidence of IP and risk of malignant transformation in the Swedish population 1960–2010
por: Elliot, Alexandra, et al.
Publicado: (2016)

A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis
por: Bousquet, Jean, et al.
Publicado: (2023)

Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity
por: D’Addio, Alex, et al.
Publicado: (2015)

Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis
por: König, Katrin, et al.
Publicado: (2015)

TOTALL: high cost of allergic rhinitis—a national Swedish population-based questionnaire study
por: Cardell, Lars-Olaf, et al.
Publicado: (2016)

Future-proofing the Cenozoic macroperforate planktonic foraminifera phylogeny of Aze & others (2011)
por: Fordham, Barry G., et al.
Publicado: (2018)

AzeR, a transcriptional regulator that responds to azelaic acid in Pseudomonas nitroreducens
por: Bez, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mt4hebkta620787qjbk07cm6v3